Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.

Author information

Affiliations

  • 1. CRC Department of Medical Oncology, Charing Cross Hospital, London, UK.
      Authors
    • Baer JC 1
    (1 author)

British Journal of Cancer, 01 Jun 1993, 67(6):1299-1302
https://doi.org/10.1038/bjc.1993.241 PMID: 8512814 PMCID: PMC1968485

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

Temozolomide (8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one) has shown promising activity in Phase I trials against some brain (glioma) and skin (melanoma, mycosis fungoides) cancers. Temozolomide and lomustine (CCNU) showed parallel toxicity in seven human tumour cell lines and this generally correlated (correlation coefficients 0.87 and 0.92 respectively) with the level of expression of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase, EC 2.1.1.63). Pretreating cells with the ATase inhibitor, O6-benzylguanine (BG), potentiated cytotoxicity to a similar degree with both drugs, but did not sensitise a cell line (ZR-75-1) expressing very low levels of this protein. When BG pretreatment was combined with repeat doses of temozolomide a dramatic potentiation (300 fold) was seen in MAWI cells, which express high levels of ATase, but not in a cell line (U373) expressing lower levels of ATase. [14C]-labelled temozolomide uptake was similar in sensitive and resistant lines. Human ATase-cDNA transfected xeroderma pigmentosum (XP) fibroblasts were more resistant than XP control cells to temozolomide and the related chloroethylating agent mitozolomide and although BG completely suppressed ATase activity in these cells, resistance was still greater than in control cells.

Free full text 

Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1993 Jun; 67(6): 1299–1302.
PMCID: PMC1968485
PMID: 8512814

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.

J. C. Baer, A. A. Freeman, E. S. Newlands, A. J. Watson, J. A. Rafferty, and G. P. Margison
Author information Copyright and License information Disclaimer

Abstract

Temozolomide (8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one) has shown promising activity in Phase I trials against some brain (glioma) and skin (melanoma, mycosis fungoides) cancers. Temozolomide and lomustine (CCNU) showed parallel toxicity in seven human tumour cell lines and this generally correlated (correlation coefficients 0.87 and 0.92 respectively) with the level of expression of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase, EC 2.1.1.63). Pretreating cells with the ATase inhibitor, O6-benzylguanine (BG), potentiated cytotoxicity to a similar degree with both drugs, but did not sensitise a cell line (ZR-75-1) expressing very low levels of this protein. When BG pretreatment was combined with repeat doses of temozolomide a dramatic potentiation (300 fold) was seen in MAWI cells, which express high levels of ATase, but not in a cell line (U373) expressing lower levels of ATase. [14C]-labelled temozolomide uptake was similar in sensitive and resistant lines. Human ATase-cDNA transfected xeroderma pigmentosum (XP) fibroblasts were more resistant than XP control cells to temozolomide and the related chloroethylating agent mitozolomide and although BG completely suppressed ATase activity in these cells, resistance was still greater than in control cells.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (825K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 1299
1299
icon of scanned page 1300
1300
icon of scanned page 1301
1301
icon of scanned page 1302
1302
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Brindley CJ, Antoniw P, Newlands ES. Plasma and tissue disposition of mitozolomide in mice. Br J Cancer. 1986 Jan;53(1):91–97. [Europe PMC free article] [Abstract] [Google Scholar]
  • Broggini M, Erba E, Morasca L, Horgan C, D'Incalci M. In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma. Cancer Chemother Pharmacol. 1986;16(2):125–128. [Abstract] [Google Scholar]
  • Bull VL, Tisdale MJ. Antitumour imidazotetrazines--XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones. Biochem Pharmacol. 1987 Oct 1;36(19):3215–3220. [Abstract] [Google Scholar]
  • Catapano CV, Broggini M, Erba E, Ponti M, Mariani L, Citti L, D'Incalci M. In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res. 1987 Sep 15;47(18):4884–4889. [Abstract] [Google Scholar]
  • Citron M, Decker R, Chen S, Schneider S, Graver M, Kleynerman L, Kahn LB, White A, Schoenhaus M, Yarosh D. O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res. 1991 Aug 15;51(16):4131–4134. [Abstract] [Google Scholar]
  • Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991 Jul 1;51(13):3367–3372. [Abstract] [Google Scholar]
  • Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368–5372. [Europe PMC free article] [Abstract] [Google Scholar]
  • Dolan ME, Stine L, Mitchell RB, Moschel RC, Pegg AE. Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 1990;2(11):371–377. [Abstract] [Google Scholar]
  • Fan CY, Potter PM, Rafferty J, Watson AJ, Cawkwell L, Searle PF, O'Connor PJ, Margison GP. Expression of a human O6-alkylguanine-DNA-alkyltransferase cDNA in human cells and transgenic mice. Nucleic Acids Res. 1990 Oct 11;18(19):5723–5727. [Europe PMC free article] [Abstract] [Google Scholar]
  • Jelinek J, Kleibl K, Dexter TM, Margison GP. Transfection of murine multi-potent haemopoietic stem cells with an E. coli DNA alkyltransferase gene confers resistance to the toxic effects of alkylating agents. Carcinogenesis. 1988 Jan;9(1):81–87. [Abstract] [Google Scholar]
  • Lee SM, Thatcher N, Margison GP. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res. 1991 Jan 15;51(2):619–623. [Abstract] [Google Scholar]
  • Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res. 1990 Nov-Dec;233(1-2):117–126. [Abstract] [Google Scholar]
  • Morten JE, Bayley L, Watson AJ, Ward TH, Potter PM, Rafferty JA, Margison GP. Upregulation of O6-alkylguanine-DNA-alkyltransferase expression and the presence of double minute chromosomes in alkylating agent selected Chinese hamster cells. Carcinogenesis. 1992 Mar;13(3):483–487. [Abstract] [Google Scholar]
  • Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L, Stevens MF. Phase I clinical trial of mitozolomide. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):801–805. [Abstract] [Google Scholar]
  • Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992 Feb;65(2):287–291. [Europe PMC free article] [Abstract] [Google Scholar]
  • Pegg AE, Byers TL. Repair of DNA containing O6-alkylguanine. FASEB J. 1992 Mar;6(6):2302–2310. [Abstract] [Google Scholar]
  • Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. [Abstract] [Google Scholar]
  • Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987 Nov 15;47(22):5846–5852. [Abstract] [Google Scholar]
  • Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, Newton CG. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. J Med Chem. 1984 Feb;27(2):196–201. [Abstract] [Google Scholar]
  • Tano K, Shiota S, Collier J, Foote RS, Mitra S. Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine. Proc Natl Acad Sci U S A. 1990 Jan;87(2):686–690. [Europe PMC free article] [Abstract] [Google Scholar]
  • Tong WP, Kirk MC, Ludlum DB. Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N'-bis(2-chloroethyl)-N-nitrosourea. Cancer Res. 1982 Aug;42(8):3102–3105. [Abstract] [Google Scholar]
  • Wasserman TH, Twentyman P. Use of a colorimetric microtiter (MTT) assay in determining the radiosensitivity of cells from murine solid tumors. Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):699–702. [Abstract] [Google Scholar]
  • Wu ZN, Chan CL, Eastman A, Bresnick E. Expression of human O6-methylguanine-DNA methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents. Cancer Res. 1992 Jan 1;52(1):32–35. [Abstract] [Google Scholar]
Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Full text links 

Read article at publisher's site: https://doi.org/10.1038/bjc.1993.241

Read article for free, from open access legal sources, via Unpaywall: https://www.nature.com/articles/bjc1993241.pdfUnpaywall

Citations & impact 

Impact metrics

105
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/43259758
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/43259758

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1038/bjc.1993.241

Supporting
Mentioning
Contrasting
3
94
1

Article citations

Go to all (105) article citations

Protocols & materials 

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.